{"id":"nerinetide-na-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nerinetide blocks the interaction between NMDA receptors and PSD-95, a scaffolding protein that couples excitotoxic calcium influx to downstream neurodegenerative pathways. By uncoupling this signaling without blocking the NMDA receptor itself, the drug preserves beneficial NMDA receptor functions while preventing ischemic neuronal damage. This mechanism is designed to provide neuroprotection in acute ischemic stroke.","oneSentence":"Nerinetide is a peptide that inhibits postsynaptic density protein 95 (PSD-95) to reduce excitotoxic neuronal death following ischemic stroke.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:55.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke (within 24 hours of symptom onset)"}]},"trialDetails":[{"nctId":"NCT04462536","phase":"PHASE3","title":"Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis","status":"COMPLETED","sponsor":"NoNO Inc.","startDate":"2020-12-06","conditions":"Stroke, Acute","enrollment":850},{"nctId":"NCT02315443","phase":"PHASE3","title":"Field Randomization of Nerinetide (NA-1) Therapy in Early Responders","status":"COMPLETED","sponsor":"NoNO Inc.","startDate":"2015-03-26","conditions":"Acute Cerebral Ischemia","enrollment":532},{"nctId":"NCT02930018","phase":"PHASE3","title":"Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke","status":"COMPLETED","sponsor":"NoNO Inc.","startDate":"2017-03-01","conditions":"Stroke, Acute","enrollment":1105}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Nerinetide (NA-1)","genericName":"Nerinetide (NA-1)","companyName":"NoNO Inc.","companyId":"nono-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nerinetide is a peptide that inhibits postsynaptic density protein 95 (PSD-95) to reduce excitotoxic neuronal death following ischemic stroke. Used for Acute ischemic stroke (within 24 hours of symptom onset).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}